NIPT Expansion Yourgene Health has an extensive NIPT and clinical screening portfolio, including IONA NIPT, NIPT workflow, and future DPYD integration, signaling opportunities to upsell integrative sequencing workflows and expanded clinical menus to labs seeking comprehensive reproductive health testing.

DPYD Opportunity Launched Yourgene Insight DPYD assay to identify patients at risk of fluoropyrimidine toxicity, creating cross-selling potential to oncology labs and hospital networks looking to optimize chemotherapy safety and personalize treatment.

Automation & Efficiency Portfolio includes Ranger automated DNA size selection and LightBench Discover, offering value to laboratories aiming to scale throughput and simplify workflows, presenting a compelling use case for customers upgrading from manual to automated solutions.

Global Footprint HQ in Manchester with facilities in Singapore, the US, and Canada positions Yourgene for regional lab partnerships and cross-border service agreements, enabling targeted multi-market sales campaigns and localized support packages.

Strategic Partnerships Part of the Novacyt group and history of collaborations suggest potential for co-marketing, joint development, and bundled offerings with related diagnostics lines to broaden addressable markets and accelerate adoption.